Cambridge, Mass.- September 15, 2010 – Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including muscle, bone, fat, red blood cells and the vasculature, today announced that it has been selected by the editors of FierceBiotech as one of the “Fierce 15” for 2010, an annual list of the top 15 most promising companies in the biotech industry.
“Acceleron is honored to be chosen by the editors of FierceBiotech as one of this year’s Fierce 15, truly an acknowledgement of our company’s innovative and creative spirit,” said John Knopf, Ph.D., Chief Executive Officer of Acceleron. “Our mission is to bring life-changing therapies to patients in need. The cutting-edge work conducted by Acceleron employees has pioneered a new field of biology and yielded a pipeline of new and powerful therapies that will help make this mission a reality.”
About the Fierce 15
FierceBiotech (http://www.fiercebiotech.com/), a daily biotech industry news and article provider, has been publishing the Fierce 15 since 2003. Every year FierceBiotech evaluates hundreds of private companies for its annual list, which is based on a variety of factors such as the strength of its technology, partnerships and a competitive market position. A complete list of “Fierce 15” companies is available online at www.fiercebiotech.com.
About Acceleron Pharma
Acceleron is a privately held biopharmaceutical company committed to discover, develop, manufacture and commercialize novel biotherapeutics that modulate the growth of red blood cells, bone, muscle, fat and the vasculature to treat musculoskeletal, metabolic and cancer-related diseases. Acceleron’s scientific approach takes advantage of its unique insight into the regenerative powers of the TGF-β superfamily of proteins. Acceleron utilizes proven biotherapeutic technologies and capitalizes on the company’s internal GMP manufacturing capability to rapidly and efficiently advance its therapeutic programs. The investors in Acceleron include Advanced Technology Ventures, Alkermes, Bessemer Ventures, Celgene, Flagship Ventures, MPM BioEquities, OrbiMed Advisors, Polaris Ventures, QVT Financial, Sutter Hill Ventures and Venrock.
For further information on Acceleron Pharma, please visit www.acceleronpharma.com
CONTACT:
Acceleron Pharma:
Steven Ertel, 617-649-9234
Vice President, Corporate Development
Paul Kidwell (Media)
Suda Communications LLC
617-296-3854